Download PDF

1. Company Snapshot

1.a. Company Description

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation.The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression.It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease.


The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease.It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F.Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine.


The company was formerly known as Sangamo BioSciences, Inc.and changed its name to Sangamo Therapeutics, Inc.in January 2017.


Sangamo Therapeutics, Inc.was incorporated in 1995 and is headquartered in Brisbane, California.

Show Full description

1.b. Last Insights on SGMO

Sangamo Therapeutics' recent performance was negatively impacted by a Q4 loss of $0.11 per share, missing revenue estimates. The company's earnings release highlighted a decline in revenue, which was partly offset by a strong pipeline of genomic medicines. The ongoing investigation by Pomerantz Law Firm on behalf of investors, citing potential claims against the company, also contributed to the negative sentiment. Furthermore, the lack of significant updates on the Fabry Disease gene therapy program, despite the expected release of phase 1/2 STAAR study data in 1H 2025, may have dampened investor enthusiasm.

1.c. Company Highlights

2. Sangamo's Progress in Gene Therapy Outweighs Financial Headwinds

Sangamo reported a loss per share of -$0.11, wider than the estimated loss of -$0.03. The company's financial performance was impacted by its research and development expenses. The revenue is expected to decline by 15.4% next year, according to analyst estimates. As per Gregory Davis, the MINT platform is a derisked technology with significant potential, which could be a future revenue driver.

Publication Date: Nov -20

📋 Highlights
  • Regulatory Validation:: FDA reaffirmed eGFR slope as primary endpoint for ST-920's accelerated approval pathway, supporting Fabry disease clinical strategy.
  • Clinical Progress:: 32 patients in the STAAR study showed a 2.0 mean eGFR slope at 52 weeks, indicating potential for long-term renal benefits.
  • New Trial Initiation:: STAND Phase I/II trial for ST-503 in neuropathic pain began with 2 sites activated, targeting 52-week data collection.
  • Prion Program Timeline:: CTA submission for prion therapy anticipated by mid-2026, with preclinical advancements ongoing.
  • Financial Update:: Received $6M from Pfizer’s buyout option exercise for zinc finger cell line licensing.

Pipeline Advances and Regulatory Clarity

The company made significant progress in its pipeline, particularly with the ST-920 program for Fabry disease. The FDA reaffirmed its agreement to use eGFR slope as an endpoint to support an accelerated approval pathway. Nathalie Dubois-Stringfellow presented encouraging clinical data at the ICIEM 2025 Conference, demonstrating a positive mean annualized eGFR slope of almost 2 at 52 weeks across all 32 patients dosed in the study. Alexander Macrae noted that regulatory clarity is established, with the primary endpoint confirmed and 1-year data shown to the agency.

Valuation Metrics and Future Prospects

The company's valuation metrics indicate a challenging financial situation, with a Price-to-Sales Ratio of 1.61 and an EV/EBITDA ratio of -2.06. The Return on Equity (ROE) is significantly negative at -293.05%. However, the progress in the pipeline and the potential of the MINT platform could drive future growth. The company's cash runway and plans to obtain additional capital are crucial in supporting its operations.

Business Development and Partnerships

The FDA meeting minutes have been shared with potential partners, and they will be part of any business development deal. Alexander Macrae mentioned that regulatory clarity can only be helpful for business development discussions. The company is making progress with the STAND study for neuropathic pain, with 2 sites activated and 2 more in setup. The high unmet medical need for the treatment is evident from the several patients who have contacted the company or the clinical sites to participate in the trial.

Platform Progress and Potential

The STAC-BBB capsid and the MINT platform are advancing, with relationships with partners like Genentech, Astellas, and Lilly. Alexander Macrae is pleased with the progress of the platform and its potential to make medicines. The MINT platform is considered a derisked technology with significant potential, and the team is working to advance it further.

3. NewsRoom

Card image cap

Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

Dec -02

Source: globenewswire.com

Card image cap

Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease

Nov -21

Source: globenewswire.com

Card image cap

Sangamo Therapeutics, Inc. (SGMO) Q3 2025 Earnings Call Transcript

Nov -07

Source: seekingalpha.com

Card image cap

Sangamo Therapeutics (SGMO) Reports Q3 Loss, Lags Revenue Estimates

Nov -06

Source: zacks.com

Card image cap

Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results

Nov -06

Source: globenewswire.com

Card image cap

Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call

Oct -30

Source: globenewswire.com

Card image cap

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025

Sep -04

Source: globenewswire.com

Card image cap

What Makes Sangamo (SGMO) a New Buy Stock

Aug -14

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (9.98%)

6. Segments

Zinc Finger Protein

Expected Growth: 9.98%

Sangamo Therapeutics' Zinc Finger Protein growth is driven by increasing adoption in gene editing, rising demand for novel cancer therapies, and strategic partnerships. The 9.98% growth rate is also fueled by advancements in gene regulation, expanding pipeline of therapeutic candidates, and growing investments in gene therapy research.

7. Detailed Products

ZFN Gene Editing

A precise and efficient gene editing technology that enables the modification of genes in living cells.

ZFP Therapeutic Proteins

A platform for the development of therapeutic proteins that can be used to treat a range of diseases, including cancer and genetic disorders.

Cell and Gene Therapy

A platform for the development of cell and gene therapies that can be used to treat a range of diseases, including cancer and genetic disorders.

Genome Regulation

A platform for the development of therapies that can be used to regulate gene expression and treat a range of diseases.

8. Sangamo Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Sangamo Therapeutics, Inc. operates in a highly competitive industry, but the threat of substitutes is mitigated by the company's focus on gene therapy and gene editing, which is a niche area with limited substitutes.

Bargaining Power Of Customers

Sangamo Therapeutics, Inc. has a diverse customer base, including pharmaceutical and biotechnology companies, which reduces the bargaining power of individual customers.

Bargaining Power Of Suppliers

Sangamo Therapeutics, Inc. relies on a few key suppliers for raw materials and equipment, which gives them some bargaining power, but the company's strong relationships with suppliers mitigate this risk.

Threat Of New Entrants

The gene therapy and gene editing industry is rapidly evolving, and new entrants with innovative technologies could potentially disrupt Sangamo Therapeutics, Inc.'s market position.

Intensity Of Rivalry

The gene therapy and gene editing industry is highly competitive, with several established players and new entrants vying for market share, which increases the intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 31.49%
Debt Cost 3.95%
Equity Weight 68.51%
Equity Cost 10.90%
WACC 8.71%
Leverage 45.97%

11. Quality Control: Sangamo Therapeutics, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Cara Therapeutics

A-Score: 4.1/10

Value: 7.4

Growth: 1.1

Quality: 5.4

Yield: 0.0

Momentum: 10.0

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Ikena Oncology

A-Score: 3.3/10

Value: 6.4

Growth: 1.8

Quality: 5.8

Yield: 0.0

Momentum: 2.0

Volatility: 4.0

1-Year Total Return ->

View Full Report
Stock-Card
HCW Biologics

A-Score: 2.8/10

Value: 8.0

Growth: 4.1

Quality: 4.9

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Sangamo Therapeutics

A-Score: 2.8/10

Value: 7.2

Growth: 3.3

Quality: 4.1

Yield: 0.0

Momentum: 2.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Eyenovia

A-Score: 2.6/10

Value: 7.6

Growth: 4.8

Quality: 3.3

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Orchestra BioMed

A-Score: 2.2/10

Value: 6.0

Growth: 2.9

Quality: 3.6

Yield: 0.0

Momentum: 0.0

Volatility: 0.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

0.5$

Current Price

0.5$

Potential

-0.00%

Expected Cash-Flows